<DOC>
	<DOCNO>NCT01081951</DOCNO>
	<brief_summary>To compare efficacy olaparib combination paclitaxel carboplatin ( AUC4 ) compare carboplatin ( AUC6 ) paclitaxel alone patient advanced ovarian cancer .</brief_summary>
	<brief_title>Study Compare Efficacy Safety Olaparib When Given Combination With Carboplatin Paclitaxel , Compared With Carboplatin Paclitaxel Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Diagnosed serous ovarian cancer Patients receive 3 previous platinum contain treatment progression free least 6 month follow end last platinum treatment At least one lesion suitable accurate repeat measurement Patients receive systemic anticancer chemotherapy , radiotherapy ( except palliative ) within two week last dose prior study treatment Hypersensitivity pre medication require treatment paclitaxel/carboplatin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>125 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Poly ( ADP ribose )</keyword>
	<keyword>polymerisation ( PARP )</keyword>
	<keyword>Platinum sensitive</keyword>
	<keyword>Advanced Serous Ovarian cancer</keyword>
	<keyword>olaparib</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>Platinum Sensitive Advanced Serous Ovarian Cancer</keyword>
</DOC>